1. Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)
   Masayoshi Miyawaki et al, 2017, Molecular and Clinical Oncology CrossRef
2. Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management
   Nakano Takayuki et al, 2018, BioMed Research International CrossRef
3. Targeted therapy and elderly people: A review
   Amaury Daste et al, 2016, European Journal of Cancer CrossRef
4. Targeted Therapies
   Amaury Daste, 2020, Encyclopedia of Gerontology and Population Aging CrossRef
5. Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications
   Oscar Juan et al, 2017, Therapeutic Advances in Medical Oncology CrossRef
6. Targeted Therapies
   Amaury Daste, 2021, Encyclopedia of Gerontology and Population Aging CrossRef
7. Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)
   Laurent Greillier et al, 2022, Cancers CrossRef
8. SIADH developed in a lung adenocarcinoma patient treated with afatinib
   K. Miyazaki et al, 2014, European Geriatric Medicine CrossRef